MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $27.50 (23.26% upside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetActions
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.Lower Price TargetOverweight$45.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016BarclaysBoost Price TargetUnderweight$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Robert W. BairdReiterated RatingNeutral$36.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Leerink SwannLower Price TargetOutperform$42.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche BankInitiated CoverageBuy$42.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2014FBR & Co.Reiterated RatingOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014Credit SuisseBoost Price TargetOutperform$43.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q314$1.67$2.61$40.83 million$42.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateHeadline
06/23/16 05:48 AMStrong Buy Calls Count For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At 1 - Investor Newswire
06/20/16 03:43 PMEnanta Pharmaceuticals Initiates Proof-of-Concept Study with …
06/20/16 10:02 AMMarket Movers: Alexco Resource Corporation (NYSEMKT:AXU), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), First ... - KC Register
06/20/16 10:02 AMEnanta Pharma (ENTA) Commences EDP-494 Proof-of-Concept Study in Two HCV Genotypes - StreetInsider.com
06/20/16 10:02 AMCan Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Surprise Analysts this Quarter? - Investor Newswire
06/20/16 09:46 AMEnanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus - [Business Wire] - Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated a proof of concept study and has begun dosing with EDP-494, a potent, pan-genotypic cyclophilin inhibitor to treat patients with genotype 1 or genotype 3 chronic hepatitis C virus.
06/16/16 08:12 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Current Analyst Ratings - Fiscal Standard
06/09/16 03:52 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Fundamental Star Rating Report - CML News
06/07/16 03:56 PMENANTA PHARMACEUTICALS INC. (NASDAQ:ENTA) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:12 AMPerformance Review for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - HNN
06/03/16 04:02 PMStock Review and Earnings Check on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - HNN
06/02/16 07:26 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Update & Estimates - Stock Tick Tock - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to post earnings of $-0.11 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 07:26 AMEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorted Shares Increased 2.06% After Market Selling - HNN - Enanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorted Shares Increased 2.06% After Market SellingHNNThe short interest to Enanta Pharmaceuticals Incorporated's float is 20.87%. The stock increased 2.45% or $0.6 during the last trading session, hitting $25.13. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has declined 2.07% since October 26, 2015 and is ...and more »
06/01/16 03:25 PMEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences - [at noodls] - Presentations to be Webcast on June 8, at 3:30 p.m. ET and June 21 at 9:00 a.m. ET WATERTOWN, Mass.--(BUSINESS WIRE)--Jun. 1, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused ...
06/01/16 07:49 AMTarget Price and Stock Performance Rundown for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - HNN - Target Price and Stock Performance Rundown for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)HNNDuring the latest trading session, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares traded +0.57%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
05/31/16 09:39 PMEnanta Pharmaceuticals Inc. (ENTA) Jumps 5.17% on May 30 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) Jumps 5.17% on May 30Equities.comEnanta Pharmaceuticals Inc. (ENTA) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 5.17% to $24.39, representing a gain of $1.2 per share. Some 267,929 shares traded hands on 2,532 trades, compared with an ...and more »
05/28/16 09:31 AMEnanta Pharmaceuticals Inc. (ENTA) Jumps 5.17% on May 27 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) Jumps 5.17% on May 27Equities.comEnanta Pharmaceuticals Inc. (ENTA) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 5.17% to $24.39, representing a gain of $1.2 per share. Some 264,444 shares traded hands on 2,527 trades, compared with an ...and more »
05/27/16 10:37 AMEarnings Review and Stock Rundown for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Wall Street Hints and News - Earnings Review and Stock Rundown for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ...and more »
05/27/16 10:37 AMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Closes At $23.19 - Stocks Daily - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Closes At $23.19Stocks DailyThe technical analysis of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stock highlights the stock is $-4.08 points away -14.82% from its 50-day MA of $27.53. It is $-5.37 or -18.63% away $28.82, the 200-day Moving Average (MA) of stock. Yesterday, the ...
05/19/16 12:04 PMENANTA PHARMACEUTICALS INC Financials -
05/18/16 08:53 AMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 16 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 16Equities.comEnanta Pharmaceuticals Inc. (ENTA) experienced unusually high volume on May. 16, as the stock lost 0.45% to a closing price of $24.46. The stock saw 488,927 shares trade hands over the course of the day on 4,437 trades. Given that the stock's average ...
05/18/16 08:53 AMRevenue Update on Enanta Pharmaceuticals Inc(NASDAQ:ENTA) - Trade Calls - Revenue Update on Enanta Pharmaceuticals Inc(NASDAQ:ENTA)Trade CallsEnanta Pharmaceuticals Inc(NASDAQ:ENTA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on May 9, 2016. Company reported revenue of $13.00M. Analysts estimated a revenue of $16.80M. Earnings ...
05/14/16 03:21 AMToday Enanta Pharmaceuticals Inc Stock Rises - Wall Street Hints and News - Today Enanta Pharmaceuticals Inc Stock RisesWall Street Hints and NewsThe stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 2.72% or $0.65 during the last trading session, hitting $24.57. About 261,497 shares traded hands. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has ...
05/13/16 05:05 PMTraders Checklist Stocks: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) , Actinium Pharmaceuticals, Inc. (NYSEMKT ... - Street Updates - Traders Checklist Stocks: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) , Actinium Pharmaceuticals, Inc. (NYSEMKT ...Street UpdatesOn 5/12/2016, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) ended trading session lower at $23.92 with -0.66%. The company traded a volume of 454.73 thousand shares as comparison to average volume of 300.09 thousand shares. During the 52 –week ...
05/12/16 10:15 PMThe SVP & GC of Enanta Pharma. (NASDAQ: ENTA) is Buying Shares - Analyst Ratings - The SVP & GC of Enanta Pharma. (NASDAQ: ENTA) is Buying SharesAnalyst RatingsToday, the SVP & GC of Enanta Pharma. (NASDAQ: ENTA), Nathaniel Gardiner, bought shares of ENTA for $12.22k. Nathaniel Gardiner increased his holding by 35.71%. In addition to Nathaniel Gardiner, one other ENTA executive reported Buy trades in the ...
05/12/16 10:15 PMStock Earnings Review: Enanta Pharmaceuticals Inc (NASDAQ:ENTA) - News Oracle - Stock Earnings Review: Enanta Pharmaceuticals Inc (NASDAQ:ENTA)News OracleLast Trade: The Company fell -1.79% and finished at $24.08. The daily volume was measured at 360,585.00 shares. The 52-week high of the share price is $51.89 and the 52-week low is $16.75. The company has a market cap of $439.07 million. The stock ...and more »
05/12/16 03:30 AMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 10 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 10Equities.comEnanta Pharmaceuticals Inc. (ENTA) experienced unusually high volume on May. 10, as the stock lost 3.65% to a closing price of $24.52. The stock saw 742,410 shares trade hands over the course of the day on 5,795 trades. Given that the stock's average ...
05/11/16 08:37 AMEnanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q2, 2016 By the Numbers -
05/10/16 03:16 PMENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/10/16 03:02 AMEdited Transcript of ENTA earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 04:04 PMENANTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
05/09/16 03:35 PMEnanta Pharmaceuticals reports 2Q loss -
05/09/16 03:30 PMEnanta Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today -
05/09/16 03:08 PMEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016 - [at noodls] - Conference Call and Webcast Today at 4:30 p.m. ET Royalty revenue from paritaprevir-containing regimens was $13.0 million Cash and marketable securities totaled $245.6 million at March 31, 2016 WATERTOWN, ...
05/09/16 06:07 AMQ2 2016 Enanta Pharmaceuticals Inc Earnings Release - After Market Close -
05/08/16 10:19 PMEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Broker Price Targets For The Coming Week - Share Trading News - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/06/16 10:10 PMEarnings Outlook on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - B.O.D.Y Confidential - Earnings Outlook on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)'s next earnings release which is expected to be posted on or around 2016-05-09. Sell-side research firms on Wall Street are expecting that the company will post EPS ...and more »
05/06/16 09:19 AMDrug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML -
05/05/16 03:16 AMAverage Analyst Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - B.O.D.Y Confidential - Average Analyst Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 3 on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/05/16 03:16 AMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 03 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 03Equities.comEnanta Pharmaceuticals Inc. (ENTA) experienced unusually high volume on May. 03, as the stock lost 5.81% to a closing price of $25.94. The stock saw 478,596 shares trade hands over the course of the day on 5,155 trades. Given that the stock's average ...
05/04/16 05:02 PMCould Enanta Pharmaceuticals Inc Recover After Today's Huge Decline? - B.O.D.Y Confidential - Could Enanta Pharmaceuticals Inc Recover After Today's Huge Decline?B.O.D.Y ConfidentialThe stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock decreased 5.81% or $1.6 during the last trading session, hitting $25.94. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has declined 25.76% since September 28, ...
05/04/16 03:22 AMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 02 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for May 02Equities.comEnanta Pharmaceuticals Inc. (ENTA) experienced unusually high volume on May. 02, as the stock lost 5.68% to a closing price of $27.54. The stock saw 588,037 shares trade hands over the course of the day on 5,283 trades. Given that the stock's average ...
05/03/16 05:09 PMEnanta Pharmaceuticals Inc. (ENTA) Drops 5.68% on May 02 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) Drops 5.68% on May 02Equities.comEnanta Pharmaceuticals Inc. (ENTA) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 5.68% to $27.54, a loss of $-1.66 per share. Starting at an opening price of $29.44 a share, the stock traded between $26.42 and $29.44 ...and more »
05/03/16 12:54 PMETF’s with exposure to Enanta Pharmaceuticals, Inc. : May 3, 2016 -
05/02/16 05:27 PMMarket Movers: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Golar LNG Ltd. (NASDAQ:GLNG), WNS (Holdings ... - KC Register - Market Movers: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Golar LNG Ltd. (NASDAQ:GLNG), WNS (Holdings ...KC RegisterEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation session to investors at the Deutsche Bank 41st Annual Healthcare Conference on May 4, 2016 at 8:00 ...
05/02/16 05:27 PMTechnical and Fundamental Insights on Enanta Pharmaceuticals Inc (NASDAQ:ENTA) - Street Report - Technical and Fundamental Insights on Enanta Pharmaceuticals Inc (NASDAQ:ENTA)Street ReportEnanta Pharmaceuticals Inc (NASDAQ:ENTA) (Trend Analysis) shares were traded with thin volume. The stock closed last trading session at $29.2, down by -1.91%, with a volume of 261,584 shares against an average amount for the last three months of ...Hot News : KeyCorp. (NYSE:KEY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), TTM Technologies Inc. (NASDAQ:TTMI ...Benchmark Monitorall 2 news articles »
05/02/16 08:00 AMEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : May 2, 2016 -
04/30/16 05:01 PMEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for April 28 - Equities.com - Enanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for April 28Equities.comEnanta Pharmaceuticals Inc. (ENTA) experienced unusually high volume on Apr. 28, as the stock lost 6.41% to a closing price of $29.77. The stock saw 606,171 shares trade hands over the course of the day on 6,171 trades. Given that the stock's average ...Enanta Pharmaceuticals Inc (ENTA) is Downgraded by JMP Securities to Mkt PerformMarket DigestEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Shorts Decreased by 6.24% After Short CoveringThe Postall 3 news articles »
04/30/16 03:32 AMJMP Securities Cuts Rating On Enanta Pharmaceuticals, Inc. (ENTA) - Finance Daily - JMP Securities Cuts Rating On Enanta Pharmaceuticals, Inc. (ENTA)Finance DailyFebruary 9 investment analysts at JP Morgan kept the company rating at “Overweight” but lowered the price expectation from $45.00 to $38.00. On February 9 Barclays left the company rating at “Underweight” and raised the price expectation to $18.00 from ...and more »
04/25/16 08:10 AMEnanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis - [Business Wire] - Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that the U.S.
About Enanta Pharmaceuticals

Enanta Pharmaceuticals logoEnanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENTA
  • CUSIP:
Key Metrics:
  • Previous Close: $22.31
  • 50 Day Moving Average: $23.96
  • 200 Day Moving Average: $27.76
  • P/E Ratio: 13.12
  • P/E Growth: 0.00
  • Market Cap: $422.93M
  • Current Quarter EPS Consensus Estimate: $1.00 EPS
Additional Links:
Enanta Pharmaceuticals (NASDAQ:ENTA) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha